Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves These Stocks
Baker Bros.
Posts Tagged ‘NASDAQ:ACAD’
Acadia Pharmaceuticals (ACAD): Baker Bros. Advisors Buys More Shares
Julian Baker and Felix Baker, the managers of Baker Bros.
Why 2U, Take-Two, Acadia, Air Lease and Acxiom Are Making Headlines Today
U.S. stock indexes are up substantially in Friday trading, with the S&P 500 hitting record highs, driven by a surprisingly strong jobs report out of the U.S.
Stumbling Biotech Stocks Spell Doom for Baker Bros. Advisors
While several hedge funds have suffered enormous losses this year due to their investments in biotech stocks, the performance of the leading biotech-focused hedge fund Baker Bros...
Why These Five Stocks Are Gaining Ground Today
The US stocks rallied on Wednesday after the dovish comments from Federal Reserve Chairwoman Janet Yellen on Tuesday. Among the prominent stocks that registered substantial gains...
Why Are These Five Stocks In Spotlight Today?
U.S. equities inched up on Monday after fresh data displayed that consumer spending rose marginally in February.
Healthcare-focused Baker Bros. Advisors’ Top Picks: Incyte, Alexion, ACADIA & More
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker.
Top 5 Healthcare Bets of World-Class Baker Bros. Advisors
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today.
ACADIA Pharmaceuticals Inc. (ACAD): Are Hedge Funds Right About This Stock?
Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns.
Why Are These Four Stocks Making A Late Surge?
Shareholders of Amicus Therapeutics, Inc. (NASDAQ:FOLD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Novavax, Inc.
Superconductor Technologies, Inc. (SCON), Pfizer Inc. (PFE), ACADIA Pharmaceuticals Inc. (ACAD): Sabby Capital’s Latest Moves in Healthcare Sector
Hal Mintz's Sabby Capital has initiated a passive stake in Superconductor Technologies, Inc. (NASDAQ:SCON) according to a schedule 13G form filed with the SEC.
ACADIA Pharmaceuticals Inc. (ACAD), Pfizer Inc. (PFE): Sabby Management Rewarded for Its Healthcare Picks
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) spiked nearly 18% during Tuesday's intraday trading and hit a 52-week high of $46.48.
Newfield Exploration Co. (NFX), ACADIA Pharmaceuticals Inc. (ACAD): How Did Andreas Halvorsen’s Small-Cap Picks Perform in Q3?
Andreas Halvorsen's Viking Global is a fund with great returns over its 15-years old history. Since its foundation, Viking's flagship fund returned on average 19% per year.
Triumph Group Inc (TGI), Intercept Pharmaceuticals Inc (ICPT), Zynga Inc (ZNGA): Viking Global’s Top 5 Small-Cap Picks
Small-cap picks from individual funds might provide investors with attractive investment options.
Baker Bros. Advisors’ Latest Moves Involve ACADIA Pharmaceuticals Inc. (ACAD) & Synageva Biopharma Corp (TRMS)
Julian Baker and Felix Baker’s hedge fund, Baker Bros. Advisors, has recently tweaked its holdings in ACADIA Pharmaceuticals Inc.
Hedge Fund News: Bill Miller, Richard Perry & Alphonse Fletcher
Legg Mason’s Bill Miller is struggling to find the ‘extraordinary’ value in the US he did last year, and said equity markets could rise even higher in 2014.
Should You Buy Optimer Pharmaceuticals, Inc. (OPTR)?
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): Revelations From This Blazing Biotech
With all of the heat generated by this biotech and its stock, it pays to pay attention to what Celgene Corporation (NASDAQ:CELG) says.
Hedge Funds Are Dumping EXACT Sciences Corporation (EXAS)
In the financial world, there are a multitude of gauges shareholders can use to analyze Mr. Market. Two of the most innovative are hedge fund and insider trading interest.
Hedge Funds Are Buying ACADIA Pharmaceuticals Inc. (ACAD)
In the eyes of many of your fellow readers, hedge funds are viewed as overrated, outdated financial tools of a forgotten age.
Do Hedge Funds and Insiders Love Halozyme Therapeutics, Inc. (HALO)?
Now, according to many investors, hedge funds are seen as delayed, outdated financial tools of an era lost to time.
Array Biopharma Inc (ARRY): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?
At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading sentiment.
Clovis Oncology Inc (CLVS), ACADIA Pharmaceuticals Inc. (ACAD): Healthcare Companies to Watch Out For
Healthcare is the most happening industry these days with new drugs on the line and investors injecting cash into companies with greater speculative growth.
ACADIA Pharmaceuticals Inc. (ACAD), Rite Aid Corporation (RAD), Questcor Pharmaceuticals Inc (QCOR): Are Any Of These Top Performers A Sell?
I began using Motley Fool’s CAPS as a way to disclose when I purchased and sold stocks, and my 97.2 rating showcases my last 10 months.
Onyx Pharmaceuticals, Inc. (ONXX), Alexion Pharmaceuticals, Inc. (ALXN): 3 Biotechs That Could Be Bought Out This Year
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
ACADIA Pharmaceuticals Inc. (ACAD), Alnylam Pharmaceuticals, Inc. (ALNY) & Celldex Therapeutics, Inc. (CLDX): Buy These Biotech Companies for Long-Term Growth
According to IBISWorld, revenue of global biotechnology companies will surge to $262 billion this year, up by 12.7%, year-over-year.
Celldex Therapeutics, Inc. (CLDX), Cytokinetics, Inc. (CYTK): Are These Top Biotech Performers Still Worth Buying?
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry.
ACADIA Pharmaceuticals Inc. (ACAD), Rite Aid Corporation (RAD) & More: Are These Top Performers Still a “Buy”?
I began using Motley Fool’s “CAPS” late last year as a way for readers to track my new positions and to show the outcome of my investments that were chosen based on the ...
ACADIA Pharmaceuticals Inc. (ACAD): Look Before You Leap With This Company
ACADIA Pharmaceuticals Inc.
Celldex Therapeutics, Inc. (CLDX), ACADIA Pharmaceuticals Inc. (ACAD): Two Biotech Stocks That Could Soon be Acquired
The final catalyst is the one that I am reviewing today. I am looking at two companies that look to be attractive acquisition targets.
Is Merrimack Pharmaceuticals Inc (MACK) Going to Burn These Hedge Funds?
According to most shareholders, hedge funds are seen as slow, old financial vehicles of the past.
Hedge Funds Are Dumping Optimer Pharmaceuticals, Inc. (OPTR)
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) was in 11 hedge funds' portfolio at the end of March. OPTR investors should be aware of a decrease in hedge fund interest lately.
ACADIA Pharmaceuticals Inc. (ACAD): What’s Next For This Biotech?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’ 1,100% gain makes it one of the best performing stocks in the market.
Hedge Funds Are Buying EXACT Sciences Corporation (EXAS)
At the moment, there are tons of metrics shareholders can use to watch Mr. Market. A pair of the most underrated are hedge fund and insider trading movement.
ACADIA Pharmaceuticals Inc. (ACAD) Soars On Hedge Fund Investment
One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are doing.
Clovis Oncology Inc (CLVS), ACADIA Pharmaceuticals Inc. (ACAD): Three Humongous Health-Care Stocks This Week
Summer doesn't officially arrive for a few more weeks, but the first week of June packed some real heat.
Here is What Hedge Funds Think About ACADIA Pharmaceuticals Inc. (ACAD)
To most market participants, hedge funds are viewed as underperforming, outdated financial vehicles of the past.
Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock?
To the average investor, there are a multitude of metrics market participants can use to track stocks. A pair of the most useful are hedge fund and insider trading movement.
A Trio Of ACADIA Pharmaceuticals Inc. (ACAD) Indicators To Watch
Nowadays, there are many facts and figures for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) investors to track, but it is smart to take note of a company's short sellers.
Three Keys to ACADIA Pharmaceuticals Inc. (ACAD)’s Future
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) had a busy couple of months.
Aegerion Pharmaceuticals, Inc. (AEGR), MannKind Corporation (MNKD): 3 Biotech Companies You Should Have Bought This Year
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
Liberty Media Corp (LMCA), Sarepta Therapeutics Inc (SRPT): Here’s What This $42 Billion Hedge Fund Company Has Been Buying
Shaw is known as a math wizard, and a quantitative investing pioneer. His firm is reportedly extremely selective, hiring less than 1% of applicants -- and Amazon.com, Inc.
Should You Avoid ACADIA Pharmaceuticals Inc. (ACAD)?
To most traders, hedge funds are seen as unimportant, outdated investment tools of the past.
ACADIA Pharmaceuticals Inc. (ACAD), Rite Aid Corporation (RAD): Are These Top Performers A Sell?
Late last year I began using Motley Fool’s My CAPS as a way for readers to track my new investments and those that fit under the guidelines in my book Taking Charge With Value...
Is Aegerion Pharmaceuticals, Inc. (AEGR) Now a Sell?
Shares of Aegerion Pharmaceuticals, Inc.
ACADIA Pharmaceuticals Inc. (ACAD): The Results That Started It All
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been on a solid run since early last year and it has continued to climb to new highs this year as well.
Should You Avoid Merrimack Pharmaceuticals Inc (MACK)?
To the average investor, there are a multitude of gauges investors can use to monitor their holdings.
ACADIA Pharmaceuticals Inc. (ACAD), Astex Pharmaceuticals, Inc. (ASTX), Pfizer Inc. (PFE), and More: This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
ACADIA Pharmaceuticals Inc. (ACAD), Pfizer Inc. (PFE): This Stock Is Fine, So What Just Happened to Mine?
While the Dow Jones Industrial Average (INDEXDJX:.DJI) continues to climb to new heights on little more than a central bank-induced asset levitation scheme and closing the day...
ACADIA Pharmaceuticals Inc. (ACAD): FDA Throws This Stock a Juicy Bone
I had recommended staying away from the company for now because it looked too risky with a long wait before the company could complete its second phase 3 trial for pimavanserin...
